Asiatic Laboratories Limited, a publicly listed pharmaceutical company, has reported robust financial performance for the first quarter ending September 30, 2025. The company released its unaudited financial statements, showing significant year-on-year growth in earnings and cash flow.

According to the disclosure, the company’s earnings per share (EPS) for the July–September 2025 period rose to Tk 1.24, compared to Tk 0.34 during the same quarter last year.

The company also reported a notable improvement in net operating cash flow per share (NOCFPS), which reached Tk 2.02, up from Tk 0.60 in the corresponding period of the previous year.

As of September 30, 2025, Asiatic Laboratories’ net asset value per share (NAVPS) stood at Tk 55.33, reflecting the company’s strengthened financial position.

Market analysts view the results as a sign of continued growth momentum in the company’s operations, supported by rising demand and improved efficiency across its product lines.